WO2024036167A3 - Methods for enhancing the anti-tumor activity of car t cells by co-expression of ch25h - Google Patents
Methods for enhancing the anti-tumor activity of car t cells by co-expression of ch25h Download PDFInfo
- Publication number
- WO2024036167A3 WO2024036167A3 PCT/US2023/071865 US2023071865W WO2024036167A3 WO 2024036167 A3 WO2024036167 A3 WO 2024036167A3 US 2023071865 W US2023071865 W US 2023071865W WO 2024036167 A3 WO2024036167 A3 WO 2024036167A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- car
- ch25h
- methods
- enhancing
- Prior art date
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 230000000259 anti-tumor effect Effects 0.000 title 1
- 230000004186 co-expression Effects 0.000 title 1
- 230000002708 enhancing effect Effects 0.000 title 1
- 108010010786 Cholesterol 25-hydroxylase Proteins 0.000 abstract 2
- 102100026533 Cytochrome P450 1A2 Human genes 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 abstract 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 abstract 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 abstract 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 abstract 1
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 abstract 1
- 229930186217 Glycolipid Natural products 0.000 abstract 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 abstract 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 abstract 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 abstract 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 abstract 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 abstract 1
- 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 abstract 1
- 102000003735 Mesothelin Human genes 0.000 abstract 1
- 108090000015 Mesothelin Proteins 0.000 abstract 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 abstract 1
- 102100036735 Prostate stem cell antigen Human genes 0.000 abstract 1
- -1 RORI Proteins 0.000 abstract 1
- 210000002865 immune cell Anatomy 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 abstract 1
- 239000002243 precursor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4637—Other peptides or polypeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464466—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
- A61K39/464468—Mesothelin [MSLN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Developmental Biology & Embryology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present disclosure provides modified immune cells or precursors thereof ( e.g., T cells) comprising sequence-defined CAR and cholesterol 25-hydroxylase (CH25H) nucleic acids. Specifically, the CAR comprises an antigen binding domain comprising specificity for a tumor associated antigen (TAA) wherein the TTA is selected from the group consisting of CD19, CD20, CD22, RORI, Mesothelin, CD33/IL3Ra, c-Met, PSMA, PSCA, Glycolipid F77, and EGFRvlll. Compositions and methods of treatment for tumor-related conditions are also provided.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202263370877P | 2022-08-09 | 2022-08-09 | |
US63/370,877 | 2022-08-09 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2024036167A2 WO2024036167A2 (en) | 2024-02-15 |
WO2024036167A3 true WO2024036167A3 (en) | 2024-03-21 |
Family
ID=89852475
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2023/071865 WO2024036167A2 (en) | 2022-08-09 | 2023-08-08 | Methods for enhancing the anti-tumor activity of car t cells by co-expression of ch25h |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024036167A2 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000023596A1 (en) * | 1998-10-22 | 2000-04-27 | Board Of Regents, The University Of Texas System | Cholesterol 25-hydroxylase |
US20210101978A1 (en) * | 2016-04-26 | 2021-04-08 | Alector Llc | Chimeric receptors and methods of use thereof |
WO2021163389A1 (en) * | 2020-02-12 | 2021-08-19 | Juno Therapeutics, Inc. | Bcma-directed chimeric antigen receptor t cell compositions and methods and uses thereof |
-
2023
- 2023-08-08 WO PCT/US2023/071865 patent/WO2024036167A2/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000023596A1 (en) * | 1998-10-22 | 2000-04-27 | Board Of Regents, The University Of Texas System | Cholesterol 25-hydroxylase |
US20210101978A1 (en) * | 2016-04-26 | 2021-04-08 | Alector Llc | Chimeric receptors and methods of use thereof |
WO2021163389A1 (en) * | 2020-02-12 | 2021-08-19 | Juno Therapeutics, Inc. | Bcma-directed chimeric antigen receptor t cell compositions and methods and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
WO2024036167A2 (en) | 2024-02-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Brakstad et al. | Detection of Staphylococcus aureus by polymerase chain reaction amplification of the nuc gene | |
Nagamune et al. | Distribution of the intermedilysin gene among the anginosus group streptococci and correlation between intermedilysin production and deep-seated infection with Streptococcus intermedius | |
Hayashi et al. | Molecular analysis of a cytotoxin‐converting phage, φCTX, of Pseudomonas aeruginosa: structure of the attP–cos–ctx region and integration into the serine tRNA gene | |
Schaller et al. | Apx toxins in Pasteurellaceae species from animals | |
Glaus et al. | Total synthesis of the bacterial RNA polymerase inhibitor ripostatin B | |
EP0268652A1 (en) | Antitumor compositions and their methods of use | |
TW200611699A (en) | Compounds, compositions and methods for prevention and treatment of inflammatory and immunoregulatory disorders and diseases | |
BRPI0415774A (en) | strain of microorganisms and processes of preparation of optimized strains and production of a molecule of interest | |
WO2024036167A3 (en) | Methods for enhancing the anti-tumor activity of car t cells by co-expression of ch25h | |
Doumbou et al. | Selection and characterization of microorganisms utilizing thaxtomin A, a phytotoxin produced by Streptomyces scabies | |
JP2017518744A (en) | Dicarbonyl reductase mutant and its application | |
Marek et al. | Characterization of bacteriophages and their carriage in Staphylococcus aureus isolated from broilers in Poland | |
WO2004010925A3 (en) | Mammalian genes involved in viral infection and tumor suppression | |
TR200600009T2 (en) | Microbial process for the preparation of pravastatin | |
Kamel et al. | Clonal VDJ recombination of the immunoglobulin heavy chain gene by PCR in classical Hodgkin’s disease | |
Rasmussen et al. | The clonal hierachy in multiple myeloma | |
Murata et al. | Stereocontrolled preparation of 1, 2-diol with quaternary chiral center | |
Ohi et al. | Synthetic Study on Top-Half (C14-C25) Fragment of Amphidinolide B, a 26-Membered Macrolide | |
Zheng et al. | Development of aRhodococcus equi–Escherichia coliPlasmid Shuttle Vector | |
Perfetti et al. | Cells with clonal light chains are present in peripheral blood at diagnosis and in apheretic stem cell harvests of primary amyloidosis | |
US4495286A (en) | Antibiotic complex producing bacterial culture | |
NAKAHAMA et al. | MICROBIAL CONVERSION OF ANTIBIOTICS. III HYDROXYLATION OF MARIDOMYCIN I AND JOSAMYCIN | |
Zampella et al. | Studies towards the synthesis of superstolide A. Synthesis and stereochemical assignment of the C (21) C (26) fragment of superstolide A | |
Rollett et al. | Immunoglobulin heavy chain sequence analysis in Waldenström's macroglobulinemia and immunoglobulin M monoclonal gammopathy of undetermined significance | |
Breneva et al. | Modern Features of Pathogenic Leptospira Isolation and Identification in Siberia and the Far East |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23853488 Country of ref document: EP Kind code of ref document: A2 |